[Paper Review] Defining a robust biological prior from Pathway Analysis to drive Network Inference

Marine Jeanmougin, Mickaël Guedj+1 more|arXiv (Cornell University)|Jan 18, 2011

Gene Regulatory Network Analysis22 references3 citations

TL;DR

This paper proposes a novel framework for gene regulatory network inference by integrating pathway-based biological priors with differential expression analysis to enhance robustness and interpretability. By refining molecular signatures through functional partner identification and applying L1-penalized Gaussian graphical models, the method identifies condition-specific regulatory networks, demonstrating its utility in identifying key dysregulated pathways in breast cancer response to therapy.

ABSTRACT

Inferring genetic networks from gene expression data is one of the most challenging work in the post-genomic era, partly due to the vast space of possible networks and the relatively small amount of data available. In this field, Gaussian Graphical Model (GGM) provides a convenient framework for the discovery of biological networks. In this paper, we propose an original approach for inferring gene regulation networks using a robust biological prior on their structure in order to limit the set of candidate networks. Pathways, that represent biological knowledge on the regulatory networks, will be used as an informative prior knowledge to drive Network Inference. This approach is based on the selection of a relevant set of genes, called the "molecular signature", associated with a condition of interest (for instance, the genes involved in disease development). In this context, differential expression analysis is a well established strategy. However outcome signatures are often not consistent and show little overlap between studies. Thus, we will dedicate the first part of our work to the improvement of the standard process of biomarker identification to guarantee the robustness and reproducibility of the molecular signature. Our approach enables to compare the networks inferred between two conditions of interest (for instance case and control networks) and help along the biological interpretation of results. Thus it allows to identify differential regulations that occur in these conditions. We illustrate the proposed approach by applying our method to a study of breast cancer's response to treatment.

Motivation & Objective

• Address the challenge of inferring reliable gene regulatory networks from high-dimensional, low-sample-size gene expression data.
• Improve the reproducibility and robustness of molecular signatures used in network inference by refining differential expression analysis.
• Integrate biologically meaningful pathway information as a structural prior to constrain the space of candidate networks.
• Enable comparative network inference between biological conditions (e.g., case vs. control) to detect differential regulatory mechanisms.
• Facilitate biological interpretation of network results by linking inferred edges to known cellular pathways and functional modules.

Proposed method

• Apply a refined differential expression analysis to identify a robust molecular signature, incorporating functional partners from protein-protein interaction (PPI) data to improve gene selection.
• Use high-confidence PPI interactions (e.g., from HPRD) to identify biologically relevant gene modules, reducing noise from low-quality interactions.
• Construct a pathway-based biological prior by mapping the refined molecular signature to known pathways, minimizing dependency on inconsistent database definitions.
• Apply the SIMoNe algorithm, which uses a weighted Lasso criterion within a Gaussian Graphical Model (GGM) framework to infer sparse, condition-specific networks.
• Incorporate pathway confidence scores into the L1 penalization to prioritize edges supported by strong biological evidence.
• Perform comparative network inference between two conditions (e.g., pCR vs. not-pCR in breast cancer) to identify differentially regulated edges.

Experimental results

Research questions

• RQ1 How can molecular signatures derived from differential expression be improved to enhance reproducibility and biological relevance?
• RQ2 To what extent can pathway-based biological priors reduce the search space of candidate networks and improve network inference accuracy?
• RQ3 Can integrating functional partners from PPI data enhance the detection of biologically meaningful genes in network inference?
• RQ4 What are the key differential regulatory mechanisms between treatment-responsive and non-responsive breast cancer subtypes?
• RQ5 How can network inference methods be adapted to compare regulatory networks across distinct biological conditions while maintaining biological interpretability?

Key findings

• The refined differential analysis, incorporating functional partners, improved the robustness of the molecular signature and enabled the inclusion of well-studied genes like AKT1 that were missed by standard differential expression alone.
• The method successfully inferred condition-specific networks, revealing that the co-expression of AKT1 and CALM3 occurs specifically in the pCR (pathological complete response) group, suggesting a potential regulatory mechanism in treatment response.
• Differential network analysis identified edges present only in the pCR or not-pCR networks, with red edges indicating connections unique to not-pCR and green edges to pCR, highlighting condition-specific regulatory changes.
• The use of pathway-based priors reduced reliance on arbitrary pathway definitions and increased the biological plausibility of inferred networks, even when using heterogeneous pathway databases.
• The integration of weighted L1 penalization based on pathway confidence improved the accuracy and interpretability of network structures, favoring biologically supported edges.
• The approach demonstrated feasibility and biological relevance in a real-world breast cancer dataset, identifying potential regulatory drivers of treatment response that could inform future therapeutic strategies.